Key Points
- Daniel Joseph Oconnell, CEO of Acumen Pharmaceuticals, sold 9,346 shares on Jan. 21 at an average price of $1.81 (≈$16,916), leaving him with 883,964 shares valued at about $1.6M; across Jan. 5–22 he sold roughly 86,013 shares in multiple blocks.
- Acumen (NASDAQ:ABOS) trades near $1.98 with a 52-week range of $0.86–$2.46 and a market cap of ~$120M, and analysts have a consensus rating of “Moderate Buy” with an average target of about $6.75.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 9,346 shares of the business's stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $1.81, for a total transaction of $16,916.26. Following the completion of the transaction, the chief executive officer directly owned 883,964 shares in the company, valued at $1,599,974.84. This trade represents a 1.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Daniel Joseph Oconnell also recently made the following trade(s):
- On Thursday, January 22nd, Daniel Joseph Oconnell sold 2,689 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.88, for a total transaction of $5,055.32.
- On Monday, January 12th, Daniel Joseph Oconnell sold 5,388 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.73, for a total value of $9,321.24.
- On Friday, January 9th, Daniel Joseph Oconnell sold 12,941 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.76, for a total value of $22,776.16.
- On Thursday, January 8th, Daniel Joseph Oconnell sold 8,143 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.82, for a total value of $14,820.26.
- On Wednesday, January 7th, Daniel Joseph Oconnell sold 37,755 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.99, for a total value of $75,132.45.
- On Tuesday, January 6th, Daniel Joseph Oconnell sold 5,102 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total value of $10,050.94.
- On Monday, January 5th, Daniel Joseph Oconnell sold 4,649 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total transaction of $9,158.53.
Acumen Pharmaceuticals Price Performance
Acumen Pharmaceuticals stock opened at $1.98 on Friday. Acumen Pharmaceuticals, Inc. has a 52-week low of $0.86 and a 52-week high of $2.46. The company has a quick ratio of 6.02, a current ratio of 6.02 and a debt-to-equity ratio of 0.29. The firm's fifty day moving average is $1.93 and its 200 day moving average is $1.73. The company has a market cap of $119.93 million, a price-to-earnings ratio of -0.89 and a beta of 0.23.
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.19. Sell-side analysts forecast that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. bought a new position in shares of Acumen Pharmaceuticals during the third quarter valued at approximately $27,000. Marex Group plc purchased a new position in Acumen Pharmaceuticals during the 2nd quarter valued at $39,000. AQR Capital Management LLC purchased a new position in Acumen Pharmaceuticals during the 1st quarter valued at $46,000. Qube Research & Technologies Ltd grew its position in Acumen Pharmaceuticals by 160.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company's stock valued at $67,000 after acquiring an additional 35,424 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Acumen Pharmaceuticals in the 2nd quarter valued at $160,000. Hedge funds and other institutional investors own 71.01% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the company. Wall Street Zen upgraded Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, December 21st. Bank of America cut their target price on Acumen Pharmaceuticals from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, November 18th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Acumen Pharmaceuticals in a research report on Friday, January 9th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Acumen Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $6.75.
Read Our Latest Stock Report on Acumen Pharmaceuticals
About Acumen Pharmaceuticals
(
Get Free Report)
Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.
The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
